Latest studies
- RecruitingPHASE3
Global Trial in APG2575 for Patients With CLL/SLL
This study is looking into a new treatment called lisaftoclax for people with a type of blood cancer called CLL/SLL. It compares adding lisaftoclax to an existing BTK inhibitor treatment versus just using the BTK inhibitor alone, for patients who have already been on BTK inhibitors.
CLL/SLLItaly - RecruitingPHASE2
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
This study is looking into a new drug, AZD8965, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if different doses of this drug are safe and effective, compared to a dummy drug, for people with IPF, including those already on other treatments.
Idiopathic Pulmonary Fibrosis (IPF)Italy - Enrolling by invitationPHASE3
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
This study looks at a new drug, LP352, for children and adults with a type of epilepsy called Developmental and Epileopathic Encephalopathy (DEE). It checks how safe and effective the drug is over a longer period for those who have already started treatment in previous studies.
Developmental and Epileptic EncephalopathyItaly - RecruitingPHASE2
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
This study is testing a new medicine, AHB-137, for people with long-term hepatitis B. It aims to see how well it works and if it's safe when added to their current treatment. It's for adults already taking medicine for hepatitis B.
Hepatitis B, ChronicItaly - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary DiseaseItaly - Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseItaly - RecruitingPHASE3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
This study is testing a drug called pridopidine for people with Amyotrophic Lateral Sclerosis (ALS), also known as Motor Neurone Disease. We want to see if pridopidine can slow down how ALS progresses and if it's safe to use. Participants will take the drug or a dummy pill daily.
Amyotrophic Lateral SclerosisItaly - RecruitingPHASE2, PHASE3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
This study is testing a new medicine, CSL300, for adults with advanced kidney disease on dialysis. It aims to see if CSL300 can improve heart health and is safe, especially for those with existing heart conditions or diabetes.
End Stage Kidney DiseaseItaly - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseItaly - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseItaly - RecruitingPHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
This study is looking for better ways to treat advanced kidney cancer that has come back after earlier treatment. Researchers want to see if a new combination of medicines, belzutifan and zanzalintinib, works better than a standard medicine, cabozantinib, at shrinking the cancer.
Renal Cell CarcinomaItaly - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseItaly - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
Carcinoma, Non-Small Cell LungItaly - Active not recruiting
Post Market Registry for GORE® TAG® Thoracic Branch Endoprosthesis
This study looks at how a special device called the GORE® TAG® Thoracic Branch Endoprosthesis works in real patients with problems in their main body artery (aorta). We want to see how safe and effective it is for conditions like aneurysms, which are dangerous bulges.
AneurysmDissection, AorticTAA Thoracoabdominal Aortic AneurysmThoracic Aortic AneurysmItaly - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
Metastatic Colorectal CancerItaly - RecruitingPHASE2, PHASE3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
This study is testing a new medicine, icotrokinra, for people in the UK with moderately to severely active Crohn's disease. Researchers want to see if it helps reduce symptoms and if it's safe to use, compared to a dummy medicine.
Crohn DiseaseItaly - RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
Non-Muscle Invasive Bladder NeoplasmsItaly - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
Advanced Breast CancerItaly - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerItaly - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Italy - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
Non Small Cell Lung CancerItaly - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseItaly - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaItaly - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisItaly - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)
This study is testing a new medicine called Tozorakimab for people with severe COPD. It aims to see if Tozorakimab can reduce flare-ups and is safe to use long-term, compared to a dummy medicine.
Chronic Obstructive Pulmonary Disease (COPD)Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
This study is testing different new drug combinations with pembrolizumab and chemotherapy for people with advanced non-small cell lung cancer who haven't had treatment yet. It's looking at how well the new combinations shrink tumors and if they have side effects.
non-small cell lung cancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICOHORT, OPEN LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) FOR TREATMENT OF ADVANCED MELANOMA REFRACTORY TO PRIOR CHECKPOINT INHIBITOR THERAPY
This study is testing new medicines, botensilimab and balstilimab, for adults with advanced melanoma. These are cancers that have not responded to previous treatments. We want to see if the new medicines can shrink the cancer.
Advanced melanoma refractory to prior checkpoint inhibitor therapyItaly - Ongoing, recruitingPhase II and Phase III (Integrated)
A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants
This study is looking at a new medicine, MK-1654, to help protect babies from a common chest infection called RSV. It will check if the medicine works well and if it's safe for both premature and full-term babies.
Prevention of RSVItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
This study looks at a new cell therapy called Tecartus for adults with a type of blood cancer called Richter Transformation that has come back or not responded to previous treatments. It aims to see how well it works and if it's safe.
Relapsed/refractory Richter Transformation (RT)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
This study looks at a new drug, pembrolizumab (Keytruda), combined with another medicine, enzalutamide. It's for men with advanced prostate cancer that has spread and isn't responding to hormone treatment. We want to see if this combination helps men live longer and slows down the cancer's growth.
Metastatic Castration-Resistant Prostate CancerItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Open-label safety study in adults and adolescents with haemophilia A with and without FVIII inhibitors switching directly from emicizumab prophylaxis to NNC0365-3769 (Mim8) prophylaxis.
This study looks at a new medicine called denecimig for people with haemophilia A. It checks how safe it is when people switch from a different medicine (emicizumab). Doctors want to see if there are any new health problems when people start taking denecimig.
Haemophilia A with or without coagulation factor VIII (FVIII) inhibitors.Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized double-blind trial to study the benefit of Colchicine in Patients with Acutely Decompensated Heart Failure
This study is looking at whether a medicine called Colchicine can help people who have heart failure that has suddenly gotten worse. Researchers want to see if it can improve how the heart works and help people feel better. It involves comparing Colchicine to a dummy pill to see the real effects.
Acute decompensated heart failureItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
This study looks at new drug combinations (BGB-A425, LBL-007, and Tislelizumab) for advanced head and neck, kidney, and lung cancers. It aims to find safe doses and see if they shrink tumours. It's an early-stage study.
Head and Neck Squamous Cell Cancer, Renal Cell Carcinoma, Non-Small Cell Lung CancerItaly - Ongoing, recruitingTherapeutic use (Phase IV)
Pan-European proof-of-concept study comparing Decentralised Clinical Trial (DCT) and hybrid approaches to conventional clinical trial approaches in patients with Type 2 diabetes mellitus treated with Toujeo®
This study is looking at new ways to run clinical trials for people with Type 2 diabetes who use Toujeo insulin. It compares traditional trial methods with more flexible approaches to see which works best for patients.
Type 2 diabetes mellitus (T2DM)Italy - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation
This study is testing a new combination of two medicines for people with advanced cancers that have a specific genetic change (called KRAS-G12C). One medicine is new (BBP-398), and it's being given with an existing one (sotorasib) to see if they work better together.
Advanced or metastatic solid tumors with a KRAS-G12C mutation, Advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS-G12C mutation and who are KRAS-G12Ci naïveItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS6 A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with very high levels of a type of fat in their blood called triglycerides. We want to see if it helps lower these levels and prevent related health problems.
Severe hypertryglyceridemiaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
MULTICENTRE, RANDOMISED, DOUBLE-BLIND, VEHICLE AND ACTIVE-CONTROLLED PHASE III STUDY EVALUATING THE EFFICACY AND SAFETY OF KETOTIFEN OPHTHALMIC SOLUTION 0.5 MG/ML COMPARED TO VEHICLE AND KETOFTIL (KETOTIFEN OPHTHALMIC SOLUTION 0.5 MG/ML) FOR THE TREATMENT OF SEASONAL ALLERGIC CONJUNCTIVITIS.
This study is looking at a new eye drop, Ketotifen, for seasonal itchy eyes caused by allergies. It compares the new drop to a similar existing one and a dummy drop to see how well it works and if it's safe for adults.
SEASONAL ALLERGIC CONJUNCTIVITISItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures
This study is testing a new medicine, EQU-001, for people with epilepsy whose seizures aren't fully controlled by their current treatment. It aims to see if the new medicine can reduce the number of seizures compared to a dummy medicine.
EpilepsyItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new medicine, Telisotuzumab Vedotin, for people with a specific type of lung cancer that hasn't been treated before. Researchers want to see how well it shrinks tumours and helps patients feel better. It's an important step in finding new treatments.
Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung CancerItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ILLUMINATE-C: A Single Arm Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 (PH1)
This study, called ILLUMINATE-C, is looking at a new medicine called Oxlumo for people with a serious kidney and liver condition called Primary Hyperoxaluria Type 1 (PH1). It's a Phase 3 study to check if the medicine is safe and helps to reduce a harmful substance called oxalate in the body.
Primary Hyperoxaluria Type 1 (PH1)Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in Subjects With Parkinson’s Disease With a Pathogenic Variant in the Glucocerebrosidase (GBA1) Gene
This study is looking into a new medicine, BIA 28-6156, for people with Parkinson's disease linked to a specific gene change (GBA1). It wants to see if the medicine can slow down how the disease affects everyday activities and movement.
Parkinson’s DiseaseItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I5T-MC-AACQ: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease
This study is looking at how different amounts of the drug donanemab affect swelling in the brain (ARIA-E) and reduce amyloid — a protein linked to Alzheimer's disease. It's for adults in the early stages of Alzheimer's.
Neurocognitive Disorders, Central Nervous System Diseases, Neurodegenerative Diseases, Nervous System Diseases, Dementia, Alzheimer’s Disease, Brain Diseases, Mental DisordersItaly - Ongoing, recruitingPhase II and Phase III (Integrated)
Evasayil TM: A placebo-controlled trial to evaluate the efficacy and safety of spesolimab in the treatment of patients with Netherton syndrome
This study is testing a new medicine, spesolimab, for Netherton syndrome. It's a trial where some people get the medicine and others get a dummy treatment (placebo) to see how well spesolimab works and if it's safe. We're looking at how it improves skin symptoms and overall well-being.
Netherton syndrome (NS)Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE MASKED, SHAM-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200220 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH UVEITIC MACULAR EDEMA
This study is testing a new eye injection to treat swelling in the eye caused by uveitis, a type of eye inflammation. It aims to see if the treatment improves eyesight and is safe for adults.
Uveitic Macular EdemaItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ARTEMIS: RAvulizumab to PRotect PaTients with Chronic Kidney DisEase (CKD) froM Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
This study looks at a new medicine called Ultomiris to see if it can protect the kidneys of people with existing kidney problems who are having heart surgery. It aims to reduce serious kidney complications after the operation.
Prevention of cardiac surgery associated acute kidney injuryItaly - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.
This study is testing a new medicine, CFT1946, for people with certain types of cancer that have a specific BRAF gene change. It checks if the medicine is safe, how well it's tolerated, and if it can shrink tumors or stop them growing, both alone and with other treatments.
BRAF-V600 Mutant Solid Tumors including Melanoma, Non-small cell lung cancer, Colorectal cancer and Anaplastic thyroid carcinoma.Italy - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ISIS 678354-CS9: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia
This study is testing a new medicine, Olezarsen, for people with high 'triglycerides' (a type of fat in the blood) and heart problems. It aims to see if the medicine can lower these fats and is safe to use.
Hypertriglyceridemia, Cardiovascular Diseases, AtherosclerosisItaly - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
This study is testing a new medicine, BMS-986360/CC-90001, for people with advanced solid cancers. It will see how safe the medicine is when given alone or with other cancer treatments like chemotherapy or nivolumab. It's an early-stage study, meaning it's the first time it will be widely used in people.
Solid TumorItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
This study is testing a new cell therapy called ALLO-501A, along with another drug called ALLO-647, for adults with a type of blood cancer called Large B-Cell Lymphoma, where previous treatments haven't worked. It aims to see how safe and effective these new treatments are.
Large B-Cell Lymphoma (LBCL)Italy